We already know that the Phase 2b monotherapy results are good. They've PRed this many times over the past 6 months. They're simply presenting the PK/PD data that supports their claims. Nothing insanely new. I find it interesting though that the CEO called this their coming out party as if NO big pharmaceutical companies have heard about them. I find it hard to believe that Gilead hasn't heard of CYDY. Maybe the delay in Pro 140 getting to market has pushed Gilead's interest back? Or maybe CYDY leadership is going to actively pursue this BPs at the conference because they now have data to support their lead drug?
News 
Market Data 
Discover 
AI
